Literature DB >> 7485361

Ocular and systemic manifestations of cerebrotendinous xanthomatosis.

J R Cruysberg1, R A Wevers, B G van Engelen, A Pinckers, A van Spreeken, J J Tolboom.   

Abstract

PURPOSE: Cerebrotendinous xanthomatosis is a storage disease that usually leads to severe mental and neurologic deterioration before the diagnosis and start of treatment are established. We identified major ocular and systemic characteristics that may enable a diagnosis to be made earlier.
METHODS: Ten patients (group 1) of the University Hospital Nijmegen, with a diagnosis of cerebrotendinous xanthomatosis, were re-examined for detailed ocular and major clinical manifestations. Meanwhile, we looked for similar but undiagnosed cases in patients (group 2) who visited the Institute of Ophthalmology during a 12-month period.
RESULTS: A diagnosis of cerebrotendinous xanthomatosis had been made in the patients of group 1 at an average age of 40 years (range, 33 to 48 years). Subsequently, six new cases (group 2) were diagnosed in patients 7 to 37 years old (average age, 18 years). Bilateral cataract was the major ocular manifestation in all 16 patients. Small irregular corticonuclear opacities, anterior polar cataracts, and dense posterior subcapsular cataracts were diagnosed at various ages (mean, 18 years; range, 4 to 40 years). Four patients showed clinical signs of optic neuropathy, whereas retinal function was normal in all patients. Other major clinical signs included a history of chronic diarrhea (since childhood), mental deterioration (mean age, 23 years), neurologic deterioration (mean age, 31 years), and tendon xanthomas (mean age, 37 years).
CONCLUSIONS: Appropriate biochemical investigations for cerebrotendinous xanthomatosis should be performed in patients with unexplained juvenile or early-onset adult cataracts, especially if these cataracts are associated with chronic diarrhea since infancy, mental retardation or deterioration, neurologic dysfunction, or xanthomas.

Entities:  

Mesh:

Year:  1995        PMID: 7485361     DOI: 10.1016/s0002-9394(14)72206-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  18 in total

1.  Children with cataract and chronic diarrhoea: cerebrotendinous xanthomatosis.

Authors:  J R M Cruysberg
Journal:  J Inherit Metab Dis       Date:  2009-03-09       Impact factor: 4.982

2.  Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings.

Authors:  M T Dotti; A Rufa; A Federico
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  Newborn screening for cerebrotendinous xanthomatosis is the solution for early identification and treatment.

Authors:  Andrea E DeBarber; Limor Kalfon; Ayalla Fedida; Vered Fleisher Sheffer; Shani Ben Haroush; Natalia Chasnyk; Efrat Shuster Biton; Hanna Mandel; Krystal Jeffries; Eric S Shinwell; Tzipora C Falik-Zaccai
Journal:  J Lipid Res       Date:  2018-08-22       Impact factor: 5.922

4.  Cerebrotendinous Xanthomatosis Presenting with Infantile Spasms and Intellectual Disability.

Authors:  Austin Larson; James D Weisfeld-Adams; Tim A Benke; Penelope E Bonnen
Journal:  JIMD Rep       Date:  2016-11-18

5.  Abnormal vascularization in mouse retina with dysregulated retinal cholesterol homeostasis.

Authors:  Saida Omarova; Casey D Charvet; Rachel E Reem; Natalia Mast; Wenchao Zheng; Suber Huang; Neal S Peachey; Irina A Pikuleva
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

6.  Cerebrotendinous xanthomatosis.

Authors:  Mahalakshmi Muniaswamy; Madhu Rengasamy; Ramesh Aravamuthan; Manoharan Krishnasamy
Journal:  Indian Dermatol Online J       Date:  2016 Jul-Aug

7.  Cholestenoic Acid is an important elimination product of cholesterol in the retina: comparison of retinal cholesterol metabolism with that in the brain.

Authors:  Natalia Mast; Rachel Reem; Ilya Bederman; Suber Huang; Pier Luigi DiPatre; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-01       Impact factor: 4.799

8.  Posttranslational modification by an isolevuglandin diminishes activity of the mitochondrial cytochrome P450 27A1.

Authors:  Casey D Charvet; James Laird; Yunfeng Xu; Robert G Salomon; Irina A Pikuleva
Journal:  J Lipid Res       Date:  2013-03-11       Impact factor: 5.922

Review 9.  The eye as a window to inborn errors of metabolism.

Authors:  B T Poll-The; L J Maillette de Buy Wenniger-Prick; P G Barth; M Duran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Cerebrotendinous xanthomatosis; a genetic condition: Clinical profile of three patients from a rural Indian family and review of literature.

Authors:  Vikas Saxena; Pavan Pradhan
Journal:  J Clin Orthop Trauma       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.